Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Sandoz Group Ltd ( (CH:SDZ) ).
Sandoz has launched Afqlir® (aflibercept) in Europe, offering an affordable treatment for retinal diseases such as neovascular age-related macular degeneration. This launch is a significant step in Sandoz’s growth strategy, enhancing its presence in the USD 15 billion anti-VEGF market and reinforcing its commitment to providing accessible biologic medicines. The approval by the European Commission and the product’s efficacy and safety matching the reference medicine Eylea® highlight its potential impact on patient care and healthcare systems.
The most recent analyst rating on (CH:SDZ) stock is a Buy with a CHF60.00 price target. To see the full list of analyst forecasts on Sandoz Group Ltd stock, see the CH:SDZ Stock Forecast page.
More about Sandoz Group Ltd
Sandoz is a global leader in affordable medicines, headquartered in Basel, Switzerland. With a history dating back to 1886, the company is known for pioneering access to healthcare through its extensive portfolio of approximately 1,300 products. Sandoz employs over 20,000 people and is committed to providing substantial healthcare savings and social impact worldwide. The company recorded net sales of USD 10.4 billion in 2024.
YTD Price Performance: 49.99%
Average Trading Volume: 688,323
Technical Sentiment Signal: Buy
Current Market Cap: CHF24.09B
See more data about SDZ stock on TipRanks’ Stock Analysis page.